| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Angiography | 44 | 2024 | 271 | 5.580 |
Why?
|
| Cerebrovascular Circulation | 23 | 2024 | 227 | 4.920 |
Why?
|
| Magnetic Resonance Imaging | 49 | 2024 | 3443 | 3.650 |
Why?
|
| Contrast Media | 43 | 2024 | 1090 | 3.300 |
Why?
|
| Image Interpretation, Computer-Assisted | 22 | 2024 | 685 | 2.570 |
Why?
|
| Infarction, Middle Cerebral Artery | 6 | 2024 | 38 | 1.840 |
Why?
|
| Gadolinium DTPA | 17 | 2024 | 264 | 1.830 |
Why?
|
| Collateral Circulation | 4 | 2020 | 35 | 1.550 |
Why?
|
| Stroke | 13 | 2024 | 982 | 1.540 |
Why?
|
| Psychomotor Performance | 2 | 2024 | 496 | 1.470 |
Why?
|
| Image Enhancement | 17 | 2016 | 567 | 1.310 |
Why?
|
| Blood Flow Velocity | 12 | 2016 | 198 | 1.230 |
Why?
|
| Perfusion Imaging | 4 | 2021 | 50 | 1.210 |
Why?
|
| Image Processing, Computer-Assisted | 21 | 2019 | 1239 | 1.140 |
Why?
|
| Brain | 14 | 2024 | 2281 | 1.130 |
Why?
|
| Artifacts | 7 | 2017 | 245 | 1.090 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 7 | 2023 | 229 | 1.070 |
Why?
|
| Cerebrovascular Disorders | 4 | 2013 | 143 | 1.060 |
Why?
|
| Imaging, Three-Dimensional | 17 | 2024 | 595 | 1.030 |
Why?
|
| Angiography, Digital Subtraction | 10 | 2016 | 99 | 1.020 |
Why?
|
| Echo-Planar Imaging | 3 | 2010 | 52 | 0.990 |
Why?
|
| Dogs | 9 | 2024 | 704 | 0.990 |
Why?
|
| Brain Ischemia | 5 | 2022 | 399 | 0.960 |
Why?
|
| Hemodynamics | 6 | 2024 | 729 | 0.950 |
Why?
|
| Feedback, Sensory | 1 | 2024 | 28 | 0.940 |
Why?
|
| Femoral Artery | 9 | 2017 | 83 | 0.910 |
Why?
|
| Brain Neoplasms | 6 | 2021 | 781 | 0.900 |
Why?
|
| Auditory Perception | 1 | 2024 | 98 | 0.890 |
Why?
|
| Norepinephrine | 4 | 2024 | 170 | 0.870 |
Why?
|
| Intracranial Arteriovenous Malformations | 4 | 2014 | 109 | 0.850 |
Why?
|
| Hand | 1 | 2023 | 133 | 0.830 |
Why?
|
| Intracranial Aneurysm | 3 | 2024 | 175 | 0.830 |
Why?
|
| Central Nervous System Vascular Malformations | 3 | 2012 | 33 | 0.810 |
Why?
|
| Blood Volume | 3 | 2013 | 49 | 0.810 |
Why?
|
| Carboxyhemoglobin | 1 | 2021 | 16 | 0.810 |
Why?
|
| Male | 72 | 2024 | 42254 | 0.800 |
Why?
|
| Adaptation, Physiological | 1 | 2024 | 314 | 0.800 |
Why?
|
| Hydralazine | 2 | 2022 | 19 | 0.790 |
Why?
|
| Female | 72 | 2024 | 46014 | 0.790 |
Why?
|
| Humans | 103 | 2024 | 89073 | 0.790 |
Why?
|
| Muscle, Skeletal | 5 | 2024 | 466 | 0.770 |
Why?
|
| Reproducibility of Results | 21 | 2023 | 2752 | 0.770 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 5 | 2024 | 57 | 0.760 |
Why?
|
| Peripheral Arterial Disease | 7 | 2017 | 94 | 0.740 |
Why?
|
| Leg | 9 | 2023 | 140 | 0.730 |
Why?
|
| Plaque, Atherosclerotic | 6 | 2024 | 59 | 0.730 |
Why?
|
| Adult | 49 | 2024 | 26508 | 0.730 |
Why?
|
| Algorithms | 11 | 2017 | 1875 | 0.710 |
Why?
|
| Cerebral Arteries | 3 | 2011 | 75 | 0.700 |
Why?
|
| Gadolinium | 4 | 2014 | 103 | 0.700 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2020 | 302 | 0.680 |
Why?
|
| Capillary Permeability | 2 | 2021 | 130 | 0.680 |
Why?
|
| Cerebral Infarction | 2 | 2017 | 72 | 0.680 |
Why?
|
| Disease Models, Animal | 9 | 2024 | 2362 | 0.670 |
Why?
|
| Isotopes | 1 | 2019 | 26 | 0.660 |
Why?
|
| Intracranial Arteriosclerosis | 4 | 2024 | 55 | 0.660 |
Why?
|
| Migraine Disorders | 1 | 2019 | 40 | 0.650 |
Why?
|
| Oxygen Radioisotopes | 2 | 2013 | 4 | 0.650 |
Why?
|
| Sensitivity and Specificity | 19 | 2021 | 2014 | 0.630 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 783 | 0.630 |
Why?
|
| Feasibility Studies | 10 | 2024 | 779 | 0.630 |
Why?
|
| Middle Aged | 46 | 2024 | 25865 | 0.620 |
Why?
|
| Organometallic Compounds | 4 | 2014 | 134 | 0.620 |
Why?
|
| Pilot Projects | 6 | 2023 | 865 | 0.580 |
Why?
|
| Cerebral Angiography | 2 | 2012 | 197 | 0.580 |
Why?
|
| Spinal Cord | 2 | 2011 | 255 | 0.580 |
Why?
|
| Pia Mater | 1 | 2016 | 5 | 0.570 |
Why?
|
| Aged | 38 | 2024 | 19078 | 0.560 |
Why?
|
| Hemangioma, Cavernous | 3 | 2021 | 69 | 0.550 |
Why?
|
| Multiple Sclerosis | 4 | 2024 | 272 | 0.540 |
Why?
|
| Blood Volume Determination | 2 | 2013 | 14 | 0.530 |
Why?
|
| Myocardium | 3 | 2014 | 571 | 0.530 |
Why?
|
| Movement | 5 | 2024 | 307 | 0.510 |
Why?
|
| Pulmonary Circulation | 1 | 2015 | 90 | 0.510 |
Why?
|
| Hemorrhage | 5 | 2023 | 278 | 0.490 |
Why?
|
| Cerebral Hemorrhage | 4 | 2023 | 338 | 0.470 |
Why?
|
| Body Water | 1 | 2013 | 35 | 0.460 |
Why?
|
| Models, Theoretical | 1 | 2016 | 491 | 0.460 |
Why?
|
| Moyamoya Disease | 1 | 2013 | 16 | 0.440 |
Why?
|
| Glioblastoma | 2 | 2019 | 265 | 0.440 |
Why?
|
| Angiography | 2 | 2011 | 208 | 0.430 |
Why?
|
| Biomarkers | 9 | 2023 | 1755 | 0.410 |
Why?
|
| Renal Circulation | 1 | 2012 | 48 | 0.400 |
Why?
|
| Hypertension, Pulmonary | 2 | 2015 | 352 | 0.400 |
Why?
|
| Oxygen | 3 | 2023 | 742 | 0.380 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 336 | 0.370 |
Why?
|
| Brain Mapping | 1 | 2014 | 564 | 0.370 |
Why?
|
| Ankle Brachial Index | 7 | 2017 | 27 | 0.360 |
Why?
|
| Animals | 21 | 2024 | 27324 | 0.350 |
Why?
|
| Cognitive Dysfunction | 3 | 2017 | 145 | 0.340 |
Why?
|
| Computer Simulation | 7 | 2017 | 1097 | 0.340 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2017 | 161 | 0.340 |
Why?
|
| White Matter | 4 | 2018 | 84 | 0.340 |
Why?
|
| Water | 2 | 2013 | 283 | 0.340 |
Why?
|
| Carotid Artery Diseases | 3 | 2019 | 98 | 0.330 |
Why?
|
| Kidney | 2 | 2012 | 1145 | 0.330 |
Why?
|
| Vascular Malformations | 1 | 2009 | 19 | 0.320 |
Why?
|
| Phantoms, Imaging | 5 | 2019 | 448 | 0.310 |
Why?
|
| Gray Matter | 2 | 2018 | 35 | 0.300 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 364 | 0.300 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2010 | 315 | 0.300 |
Why?
|
| Ischemia | 2 | 2021 | 251 | 0.290 |
Why?
|
| Brain Diseases | 1 | 2008 | 185 | 0.290 |
Why?
|
| Forearm | 1 | 2007 | 31 | 0.290 |
Why?
|
| Carotid Arteries | 5 | 2007 | 127 | 0.280 |
Why?
|
| Vasodilator Agents | 3 | 2024 | 146 | 0.280 |
Why?
|
| Permeability | 4 | 2021 | 137 | 0.280 |
Why?
|
| Young Adult | 7 | 2024 | 6289 | 0.280 |
Why?
|
| Brain Edema | 2 | 2018 | 58 | 0.270 |
Why?
|
| Renal Artery Obstruction | 4 | 2007 | 38 | 0.270 |
Why?
|
| Upper Extremity | 2 | 2023 | 52 | 0.250 |
Why?
|
| Wrist | 1 | 2004 | 22 | 0.250 |
Why?
|
| Walking | 4 | 2014 | 89 | 0.250 |
Why?
|
| Time Factors | 13 | 2018 | 5320 | 0.240 |
Why?
|
| Artificial Intelligence | 1 | 2007 | 322 | 0.240 |
Why?
|
| Acoustic Stimulation | 1 | 2024 | 131 | 0.230 |
Why?
|
| Retrospective Studies | 15 | 2024 | 9003 | 0.230 |
Why?
|
| Aged, 80 and over | 10 | 2017 | 6777 | 0.230 |
Why?
|
| Heart | 3 | 2017 | 573 | 0.230 |
Why?
|
| Prospective Studies | 9 | 2023 | 4273 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1401 | 0.230 |
Why?
|
| Bicycling | 1 | 2023 | 12 | 0.220 |
Why?
|
| Myalgia | 1 | 2023 | 7 | 0.220 |
Why?
|
| Cattle | 2 | 2021 | 375 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2657 | 0.220 |
Why?
|
| Motor Skills | 1 | 2024 | 79 | 0.220 |
Why?
|
| Motor Neurons | 1 | 2004 | 174 | 0.220 |
Why?
|
| Neural Pathways | 1 | 2004 | 319 | 0.210 |
Why?
|
| Aortic Diseases | 3 | 2007 | 100 | 0.210 |
Why?
|
| Tomography, Emission-Computed | 1 | 2002 | 102 | 0.210 |
Why?
|
| Blood Vessel Prosthesis | 3 | 2010 | 242 | 0.200 |
Why?
|
| Dopamine | 1 | 2024 | 276 | 0.200 |
Why?
|
| Deception | 1 | 2022 | 20 | 0.200 |
Why?
|
| Photic Stimulation | 1 | 2024 | 501 | 0.200 |
Why?
|
| Principal Component Analysis | 1 | 2002 | 160 | 0.200 |
Why?
|
| Quality of Life | 3 | 2023 | 1662 | 0.200 |
Why?
|
| Cerebral Cortex | 2 | 2016 | 589 | 0.200 |
Why?
|
| Visual Perception | 1 | 2024 | 326 | 0.190 |
Why?
|
| Predictive Value of Tests | 8 | 2017 | 1715 | 0.190 |
Why?
|
| Lipids | 3 | 2017 | 271 | 0.180 |
Why?
|
| Treatment Outcome | 7 | 2023 | 8203 | 0.180 |
Why?
|
| Hepatic Encephalopathy | 2 | 2018 | 39 | 0.180 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2009 | 61 | 0.180 |
Why?
|
| Reference Values | 4 | 2013 | 661 | 0.180 |
Why?
|
| Brain Stem | 1 | 2021 | 167 | 0.180 |
Why?
|
| Vasoconstrictor Agents | 1 | 2020 | 56 | 0.180 |
Why?
|
| Software | 3 | 2017 | 665 | 0.170 |
Why?
|
| Healthy Aging | 1 | 2019 | 10 | 0.170 |
Why?
|
| Arteries | 1 | 2000 | 180 | 0.170 |
Why?
|
| Models, Cardiovascular | 3 | 2016 | 106 | 0.170 |
Why?
|
| Polyethylene Glycols | 1 | 2021 | 358 | 0.170 |
Why?
|
| Vascular Calcification | 2 | 2017 | 51 | 0.170 |
Why?
|
| Middle Cerebral Artery | 1 | 2019 | 20 | 0.170 |
Why?
|
| Aneurysm | 2 | 2017 | 60 | 0.170 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 66 | 0.170 |
Why?
|
| Natalizumab | 1 | 2018 | 21 | 0.160 |
Why?
|
| Hypercapnia | 1 | 2019 | 44 | 0.160 |
Why?
|
| Cohort Studies | 7 | 2021 | 2863 | 0.160 |
Why?
|
| Microspheres | 1 | 2019 | 108 | 0.160 |
Why?
|
| Transcriptome | 2 | 2021 | 628 | 0.160 |
Why?
|
| Muscle Contraction | 3 | 2023 | 284 | 0.160 |
Why?
|
| Brain Infarction | 1 | 2018 | 22 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 85 | 0.150 |
Why?
|
| Severity of Illness Index | 7 | 2018 | 1837 | 0.150 |
Why?
|
| Heart Ventricles | 2 | 2016 | 779 | 0.150 |
Why?
|
| Dependent Ambulation | 1 | 2017 | 3 | 0.150 |
Why?
|
| Aorta, Thoracic | 3 | 2007 | 166 | 0.150 |
Why?
|
| Mobility Limitation | 1 | 2017 | 20 | 0.150 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2017 | 18 | 0.140 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2017 | 8 | 0.140 |
Why?
|
| Tissue Distribution | 2 | 2014 | 293 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 84 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 162 | 0.140 |
Why?
|
| Sample Size | 1 | 2017 | 128 | 0.140 |
Why?
|
| Breath Holding | 1 | 2016 | 22 | 0.140 |
Why?
|
| Perfusion | 3 | 2022 | 235 | 0.140 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2016 | 47 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 412 | 0.140 |
Why?
|
| Swine | 8 | 2016 | 581 | 0.130 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2016 | 24 | 0.130 |
Why?
|
| Coronary Circulation | 1 | 2016 | 131 | 0.130 |
Why?
|
| Subtraction Technique | 1 | 2016 | 132 | 0.130 |
Why?
|
| Kinetics | 2 | 2017 | 1528 | 0.130 |
Why?
|
| Cognition Disorders | 1 | 2017 | 235 | 0.130 |
Why?
|
| Ovarian Diseases | 1 | 2014 | 32 | 0.120 |
Why?
|
| Chicago | 5 | 2019 | 1423 | 0.120 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2014 | 56 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 988 | 0.120 |
Why?
|
| Infertility, Female | 1 | 2014 | 96 | 0.110 |
Why?
|
| Metabolic Clearance Rate | 1 | 2013 | 120 | 0.110 |
Why?
|
| Thalamus | 3 | 2022 | 134 | 0.110 |
Why?
|
| Embolization, Therapeutic | 2 | 2014 | 262 | 0.110 |
Why?
|
| Albumins | 1 | 2014 | 129 | 0.110 |
Why?
|
| Tomography, Optical Coherence | 1 | 2014 | 136 | 0.110 |
Why?
|
| Electromyography | 2 | 2023 | 193 | 0.110 |
Why?
|
| Ovary | 1 | 2014 | 261 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2017 | 575 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 894 | 0.110 |
Why?
|
| Molecular Imaging | 1 | 2014 | 65 | 0.110 |
Why?
|
| Nerve Net | 1 | 2017 | 372 | 0.110 |
Why?
|
| Arteriovenous Fistula | 1 | 2013 | 53 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 3 | 2011 | 275 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 848 | 0.100 |
Why?
|
| Magnetic Fields | 1 | 2012 | 11 | 0.100 |
Why?
|
| Biomechanical Phenomena | 2 | 2024 | 473 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2024 | 1855 | 0.100 |
Why?
|
| Statistics as Topic | 1 | 2013 | 234 | 0.100 |
Why?
|
| Vascular Surgical Procedures | 2 | 2016 | 149 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 193 | 0.100 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1067 | 0.090 |
Why?
|
| Creatinine | 1 | 2011 | 293 | 0.090 |
Why?
|
| Elastomers | 1 | 2010 | 3 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2011 | 148 | 0.090 |
Why?
|
| Citrates | 1 | 2010 | 28 | 0.090 |
Why?
|
| Comorbidity | 4 | 2016 | 948 | 0.090 |
Why?
|
| Pulmonary Veins | 1 | 2011 | 93 | 0.090 |
Why?
|
| Area Under Curve | 1 | 2010 | 337 | 0.090 |
Why?
|
| Regional Blood Flow | 3 | 2017 | 198 | 0.090 |
Why?
|
| Angioplasty, Balloon | 2 | 2007 | 96 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2021 | 369 | 0.090 |
Why?
|
| Cicatrix | 1 | 2009 | 68 | 0.080 |
Why?
|
| Monitoring, Intraoperative | 1 | 2009 | 110 | 0.080 |
Why?
|
| Stereotaxic Techniques | 1 | 2009 | 80 | 0.080 |
Why?
|
| Bevacizumab | 1 | 2010 | 287 | 0.080 |
Why?
|
| Polymers | 1 | 2010 | 194 | 0.080 |
Why?
|
| Pulmonary Artery | 1 | 2011 | 319 | 0.080 |
Why?
|
| Machine Learning | 2 | 2021 | 257 | 0.080 |
Why?
|
| Biocompatible Materials | 1 | 2010 | 198 | 0.080 |
Why?
|
| Risk Factors | 5 | 2019 | 5466 | 0.080 |
Why?
|
| Calibration | 2 | 2006 | 104 | 0.080 |
Why?
|
| Random Allocation | 2 | 2014 | 328 | 0.080 |
Why?
|
| Stents | 2 | 2009 | 395 | 0.080 |
Why?
|
| Arteriosclerosis | 2 | 2006 | 112 | 0.080 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2007 | 2 | 0.080 |
Why?
|
| Polytetrafluoroethylene | 1 | 2007 | 74 | 0.070 |
Why?
|
| Carotid Artery, External | 1 | 2007 | 8 | 0.070 |
Why?
|
| Tunica Intima | 1 | 2007 | 60 | 0.070 |
Why?
|
| Ferrosoferric Oxide | 1 | 2007 | 19 | 0.070 |
Why?
|
| Magnetite Nanoparticles | 1 | 2007 | 27 | 0.070 |
Why?
|
| Dextrans | 1 | 2007 | 79 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 413 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2010 | 256 | 0.070 |
Why?
|
| ROC Curve | 3 | 2019 | 781 | 0.070 |
Why?
|
| Oxides | 1 | 2007 | 43 | 0.070 |
Why?
|
| Organ Size | 2 | 2018 | 369 | 0.070 |
Why?
|
| Magnetics | 1 | 2006 | 41 | 0.070 |
Why?
|
| Iron | 1 | 2007 | 168 | 0.070 |
Why?
|
| Lower Extremity | 2 | 2023 | 87 | 0.070 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2006 | 99 | 0.070 |
Why?
|
| Necrosis | 2 | 2017 | 209 | 0.060 |
Why?
|
| Disease Progression | 1 | 2010 | 1488 | 0.060 |
Why?
|
| Adolescent | 4 | 2014 | 9237 | 0.060 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2006 | 71 | 0.060 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2005 | 14 | 0.060 |
Why?
|
| H-Reflex | 1 | 2004 | 8 | 0.060 |
Why?
|
| Radial Nerve | 1 | 2004 | 3 | 0.060 |
Why?
|
| Muscle Spindles | 1 | 2004 | 5 | 0.060 |
Why?
|
| Spinal Nerve Roots | 1 | 2004 | 17 | 0.060 |
Why?
|
| Median Nerve | 1 | 2004 | 12 | 0.060 |
Why?
|
| Smoking | 2 | 2014 | 620 | 0.060 |
Why?
|
| Afferent Pathways | 1 | 2004 | 78 | 0.060 |
Why?
|
| Weight-Bearing | 1 | 2024 | 67 | 0.060 |
Why?
|
| Fibrosis | 2 | 2016 | 234 | 0.060 |
Why?
|
| Elasticity | 1 | 2024 | 96 | 0.060 |
Why?
|
| Sex Factors | 1 | 2007 | 1063 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 967 | 0.060 |
Why?
|
| Neural Inhibition | 1 | 2004 | 97 | 0.060 |
Why?
|
| Interneurons | 1 | 2004 | 94 | 0.060 |
Why?
|
| Logistic Models | 2 | 2021 | 1212 | 0.060 |
Why?
|
| Levodopa | 1 | 2024 | 36 | 0.060 |
Why?
|
| Electric Stimulation | 1 | 2004 | 354 | 0.060 |
Why?
|
| Temporal Lobe | 2 | 2016 | 176 | 0.060 |
Why?
|
| Quadriceps Muscle | 1 | 2023 | 5 | 0.060 |
Why?
|
| Heel | 1 | 2023 | 4 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2006 | 335 | 0.050 |
Why?
|
| Age Factors | 1 | 2007 | 1867 | 0.050 |
Why?
|
| Limbic System | 1 | 2022 | 23 | 0.050 |
Why?
|
| Biophysical Phenomena | 1 | 2002 | 124 | 0.050 |
Why?
|
| Biophysics | 1 | 2002 | 153 | 0.050 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2003 | 202 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2002 | 150 | 0.050 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2002 | 109 | 0.050 |
Why?
|
| Observer Variation | 3 | 2015 | 610 | 0.050 |
Why?
|
| Linear Models | 3 | 2009 | 421 | 0.050 |
Why?
|
| Aorta, Abdominal | 1 | 2001 | 59 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 360 | 0.050 |
Why?
|
| Constriction, Pathologic | 2 | 2013 | 217 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2001 | 240 | 0.050 |
Why?
|
| Exercise Test | 2 | 2013 | 165 | 0.050 |
Why?
|
| Child | 2 | 2003 | 7149 | 0.050 |
Why?
|
| Learning | 1 | 2024 | 285 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2021 | 117 | 0.050 |
Why?
|
| Vitamin D | 1 | 2023 | 268 | 0.050 |
Why?
|
| Plasma | 1 | 2020 | 51 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 153 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2013 | 901 | 0.040 |
Why?
|
| Exercise | 1 | 2023 | 322 | 0.040 |
Why?
|
| Prevalence | 2 | 2014 | 1240 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2018 | 59 | 0.040 |
Why?
|
| Atrophy | 1 | 2018 | 119 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 312 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 421 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2018 | 181 | 0.040 |
Why?
|
| Clinical Deterioration | 1 | 2018 | 22 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 308 | 0.040 |
Why?
|
| Walk Test | 1 | 2017 | 23 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2017 | 74 | 0.040 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2016 | 33 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2017 | 140 | 0.030 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2017 | 63 | 0.030 |
Why?
|
| Blood Vessels | 2 | 2010 | 94 | 0.030 |
Why?
|
| Acute Coronary Syndrome | 1 | 2016 | 30 | 0.030 |
Why?
|
| Genotype | 1 | 2021 | 1848 | 0.030 |
Why?
|
| Limbic Lobe | 1 | 2016 | 1 | 0.030 |
Why?
|
| Infant | 1 | 2003 | 3147 | 0.030 |
Why?
|
| Putamen | 1 | 2016 | 13 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2003 | 3717 | 0.030 |
Why?
|
| Aging | 1 | 2020 | 716 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2016 | 131 | 0.030 |
Why?
|
| Electrocardiography | 2 | 2007 | 493 | 0.030 |
Why?
|
| Parietal Lobe | 1 | 2016 | 119 | 0.030 |
Why?
|
| Oscillometry | 1 | 2014 | 25 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 859 | 0.030 |
Why?
|
| Shear Strength | 1 | 2013 | 18 | 0.030 |
Why?
|
| Critical Illness | 1 | 2016 | 306 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 3773 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2013 | 253 | 0.030 |
Why?
|
| Intermittent Claudication | 1 | 2012 | 20 | 0.030 |
Why?
|
| Computer Systems | 1 | 2012 | 79 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 2291 | 0.020 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2011 | 9 | 0.020 |
Why?
|
| Meglumine | 1 | 2011 | 38 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 232 | 0.020 |
Why?
|
| Actigraphy | 1 | 2011 | 59 | 0.020 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2011 | 60 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2011 | 136 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2010 | 50 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2010 | 141 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 3657 | 0.020 |
Why?
|
| Angioplasty | 1 | 2009 | 70 | 0.020 |
Why?
|
| Monocytes | 1 | 2010 | 218 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 433 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 1706 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2007 | 42 | 0.020 |
Why?
|
| Renal Artery | 1 | 2007 | 52 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2010 | 711 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2007 | 152 | 0.020 |
Why?
|
| Thrombosis | 1 | 2010 | 302 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2007 | 122 | 0.020 |
Why?
|
| Models, Biological | 1 | 2014 | 1764 | 0.020 |
Why?
|
| Macrophages | 1 | 2010 | 571 | 0.020 |
Why?
|
| Iohexol | 1 | 2006 | 25 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 306 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 373 | 0.020 |
Why?
|
| Swine, Miniature | 1 | 2006 | 50 | 0.020 |
Why?
|
| Blood | 1 | 2006 | 69 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2005 | 33 | 0.020 |
Why?
|
| Thigh | 1 | 2004 | 39 | 0.020 |
Why?
|
| Catheterization, Peripheral | 1 | 2005 | 60 | 0.010 |
Why?
|
| Inflammation | 1 | 2010 | 971 | 0.010 |
Why?
|
| Abdomen | 1 | 2004 | 122 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 2612 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 2002 | 126 | 0.010 |
Why?
|
| Injections | 1 | 2001 | 116 | 0.010 |
Why?
|
| Models, Animal | 1 | 2002 | 276 | 0.010 |
Why?
|
| Mice | 1 | 2014 | 11742 | 0.010 |
Why?
|
| Carotid Stenosis | 1 | 1999 | 115 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 1999 | 463 | 0.010 |
Why?
|